Quarterly report pursuant to Section 13 or 15(d)

Stockholders' Equity (Deficit)

Stockholders' Equity (Deficit)
9 Months Ended
Jun. 30, 2020
Equity [Abstract]  
Stockholders' Equity (Deficit)
(9) Stockholders’ Equity (Deficit)


Common stock


Prior to the Merger, during the six months ended March 31, 2020, the Company sold 186,075 shares of common stock and issued warrants to purchase 93,038 shares of common stock with an exercise price of $29.32 per share for net proceeds of $4,070,030. In addition, the Company issued 8,526 shares of common stock upon conversion of outstanding promissory notes with an outstanding principal balance of $200,000 at the time of conversion.


Upon consummation of the Merger, the Company issued 547,639 common shares and 206,371 warrants to legacy Chanticleer shareholders. The warrants are to purchase shares of common stock with exercise prices ranging from $0.01 per share to $1,820 per share and a weighted average exercise price of $26.60 per share.


On April 1, 2020, the Company sold 1,699,232 shares of common stock to new investors for net proceeds of $15,000,000 in a private placement. The new investors also received 3,300,066 Series A warrants with an exercise price of $5.3976 and 2,247,726 Series B warrants with an exercise price of $0.0001. An advisor for the private placement was issued 453,128 shares of common stock.


The Company issued 757,933 shares to acquire the nets assets of Relief (see Note 4).


During the nine months ended June 30, 2019, the Company sold 329,708 shares of common stock in exchange for net proceeds of $2,382,000 and issued 162,522 shares of common stock upon conversion promissory notes with an aggregate outstanding principal balance of $1,250,000 at the time of conversion.


Common stock Warrants


As of June 30, 2020, the following equity-classified warrants and related terms were outstanding:


    Warrants     Exercise     Expiration
    Outstanding     Price     Date
Warrants     105,812     $ 29.32     October 1, 2022 - March 10, 2023
Chanticleer warrants     206,341       $0.01 - $1,820     October 1, 2020 - December 17, 2028
Series A warrants     3,300,066     $ 5.40     April 16, 2025
Series B warrants     2,247,726     $ 0.0001     April 16, 2025


The Series A and Series B warrants include certain down-round protection provisions based upon the Company’s volume weighted average closing stock price and in the event the Company were to sell shares of its common stock at a price below the Series A warrant exercise price then in effect. The Company determined these provisions do not preclude equity classification as the provisions do not violate the indexation guidance, as prescribed within ASC 815-40.